Article Text

other Versions

PDF
Anti-PDGFR-α antibodies measured by non-bioactivity assays are not specific of systemic sclerosis
  1. Eva Balada (ebalada{at}ir.vhebron.net)
  1. Vall d'Hebron Research Institute, Spain
    1. Carmen-Pilar Simeón-Aznar
    1. Vall d'Hebron Research Institute, Spain
      1. Josep Ordi-Ros
      1. Vall d'Hebron Research Institute, Spain
        1. Maria Rosa-Leyva
        1. Vall d'Hebron Research Institute, Spain
          1. Albert Selva-O’Callaghan
          1. Vall d'Hebron Research Institute, Spain
            1. Josep Pardos-Gea
            1. Vall d'Hebron Research Institute, Spain
              1. Vicente Fonollosa-Pla
              1. Vall d'Hebron Research Institute, Spain
                1. Miquel Vilardell-Tarrés
                1. Vall d'Hebron Research Institute, Spain

                  Abstract

                  Objective: To evaluate the presence of anti-PDGFR-α antibodies by immunological methods in patients with systemic sclerosis (SSc).

                  Methods: Fifty-eight women diagnosed with SSc and 36 healthy women controls were included. IgG anti-PDGFR-α were measured by ELISA and immunoblot. Associations with clinical and immunological findings were also studied.

                  Results: Non-statistically significant differences were detected between SSc patients and controls: median value: 0.287 (range: 0-2.06) vs. median value: 0.226 (range: 0-2.94), respectively (p = 0.583). None correlation between the presence of anti-PDGFR-α antibodies and clinical and serologic features was observed. Sera from SSc patients and healthy people who showed high titers of anti-PDGFR-α antibodies by ELISA recognized the same band corresponding to PDGFR-α by immunoblot.

                  Conclusion: Although anti-PDGFR-α antibodies seem to be disease-specific when determined by bioactivity assays, these antibodies are also detected in normal subjects when immunological methods are performed. Thus, our study leads to the hypothesis that anti-PDGFR-α antibodies may arise from natural autoantibodies. It is possible that SSc-autoantibodies recognize a different epitope on the PDGFR-α molecule which triggers its stimulatory effect when analyzed by functional assays. Alternatively, naturally occurring autoantibodies would even become pathogenic after suffering some kind of affinity maturation and class switching in genetically susceptible individuals.

                  • anti-PDGFR-alpha
                  • autoimmunity
                  • systemic sclerosis

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.